Abstracts Archive - Page 2398 of 2425 - ACR Meeting Abstracts

Abstract Number: 364 • 2012 ACR/ARHP Annual Meeting
Moderate Rheumatoid Arthritis Despite Methotrexate Treatment: Risk of Radiographic Progression
Bruno Fautrel¹, Gaia Gallo², Yves Brault³ and Henk Nab², ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²Pfizer Europe, Rome, Italy, ³Pfizer, Paris, France
Background/Purpose: Clinical remission or low disease activity are the main goals of rheumatoid arthritis (RA) treatment and European League Against Rheumatism guidelines recommend switching treatment…
Abstract Number: 365 • 2012 ACR/ARHP Annual Meeting
Improvement of Health-Related Quality of Life in RA Patients Treated with Biologics – One-Year Follow-up Data of the German Biologics Register Rabbit
Kerstin Gerhold¹, Adrian Richter², Matthias Schneider³, Hans Joachim Bergerhausen⁴, Winfried Demary⁵, Anke Liebhaber⁶, Joachim Listing⁷, Angela Zink⁸ and Anja Strangfeld⁹, ¹Programme Area of Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ⁴Klinik für Rheumatologie, Wedau Kliniken - Klinikum Duisburg, Duisburg, Germany, ⁵Private Practice, Hildesheim, Germany, ⁶Private Practice, Halle, Germany, ⁷German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ⁸Epidemiology Unit, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ⁹Programme Area Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany
Background/Purpose: Health‐related quality of life (HRQoL) has been increasingly recognized as a crucial indicator of disease burden in chronic diseases such as rheumatoid arthritis (RA).…
Abstract Number: 366 • 2012 ACR/ARHP Annual Meeting
Efficacy of Methotrexate (MTX) According to Anti-Citrullinated Protein Antibody (ACPA) Status in an Early Inflammatory Arthritis Cohort
Sarah C. Horton¹, David Pickles¹, Paul Emery¹, Maya H. Buch² and Jane E. Freeston¹, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Data suggests patients with early, ACPA negative, rheumatoid (RA) and undifferentiated arthritis (UA) are less likely to achieve remission with MTX at 4 months…
Abstract Number: 367 • 2012 ACR/ARHP Annual Meeting
Improved Fatigue-Related Quality of Life in CAPRA-2, a 12 Week Study of 5-Mg Modified (Delayed) Release Prednisone in Rheumatoid Arthritis
Rieke Alten¹, Amy Grahn², Patricia Rice³ and Frank Buttgereit⁴, ¹Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, ²Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ³Statistics, CliniRx Research, Naperville, IL, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Quality of life in rheumatoid arthritis (RA) patients can be improved by reducing the common symptom of fatigue caused by disease related factors such…
Abstract Number: 368 • 2012 ACR/ARHP Annual Meeting
Impact of Etanercept-Methotrexate Therapy On Patient-Reported Outcomes in Rheumatoid Arthritis Patients with up to 12 Months of Symptoms
Paul Emery¹, Piotr Wiland², Wolfgang Spieler³, Jean Dudler⁴, Stefanie Gaylord⁵, Theresa Williams⁵, Ronald Pedersen⁵, Andrew S. Koenig⁵, Bonnie Vlahos⁵ and Sameer Kotak⁶, ¹Department of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom, ²Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, ³Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁴Department of Rheumatology, University Hospital of Lausanne, Lausanne, Switzerland, ⁵Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁶Department of Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) are critical in evaluating RA treatment effects on function and health-related quality of life (HR-QoL).…
Abstract Number: 369 • 2012 ACR/ARHP Annual Meeting
Differences in Short-Term Radiographic Progression Following Early Response to Adalimumab Plus Methotrexate Vs. Methotrexate Alone
Ronald F. van Vollenhoven¹, James W. Shaw², Mary A. Cifaldi³, James Signorovitch⁴, Eric Q. Wu⁴, Thomas Samuelson⁴, Elizabeth Faust⁴ and Paul Emery⁵, ¹Karolinska Institute, Stockholm, Sweden, ²Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, ³Abbott Laboratories, Abbott Park, IL, ⁴Analysis Group, Inc., Boston, MA, ⁵Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom
Background/Purpose: To prevent disease progression, treat-to-target recommendations for rheumatoid arthritis (RA) include the evaluation and adjustment of drug therapy at least every 3 months until…
Abstract Number: 330 • 2012 ACR/ARHP Annual Meeting
Fut1 Plays A Unique Role in K/BxN Serum Transfer Arthritis by Regulating Angiogenesis and Adhesion Molecule Expression
M. Asif Amin¹, Phillip L. Campbell², Takeo Isozaki³, Jeffrey H. Ruth³, Jonathan Vargo², Steven E. Domino⁴ and Alisa E. Koch⁵, ¹Department of Medicine, University of Michigan Medical School, Ann Arbor, MI, ²Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, ³Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, ⁴Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI, ⁵Internal Medicine - Rheumatology, University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Angiogenesis is important in rheumatoid arthritis (RA) synovial tissue proliferation and leukocyte ingress into the inflamed joints. Fucosyltransferases (Futs) are involved in the synthesis…
Abstract Number: 331 • 2012 ACR/ARHP Annual Meeting
PDL241, a Novel Humanized Monoclonal Antibody, Reveals CD319 As a Therapeutic Target for Rheumatoid Arthritis
Michel P.M. Vierboom¹, Jacky Woo², Hakju Kwon², Debra Chao², Shiming Ye², Jianmin Li², Karen Lin², Irene Tang², Nicole Belmar², Taymar Hartman², Elia Breedveld¹, Bert A. ‘t Hart¹ and Gary C. Starling², ¹Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ²Abbott Biotherapeutics, Redwood City, CA
Background/Purpose: Current therapies have shown tremendous progress in the treatment of rheumatoïd arthritis (RA). However, a substantial group of RA patients are still refractory to…
Abstract Number: 332 • 2012 ACR/ARHP Annual Meeting
Blockade of CTGF Restores Aberrant Ostoclastgenesis in Collagen Induced Arthritis (CIA) Mice Through Inhibition of Th-17 Differentiation
Kazuhisa Nozawa¹, Maki Fujishiro², Ayako Yamaguchi¹, Mikiko Kawasaki², Shouzou Ichinose², Mitsuaki Yanagida², Kazuhisa Iwabuchi², Keigo Ikeda³, Shinji Morimoto⁴, Megumi Morioka⁵, Yoshinari Takasaki⁶ and Iwao Sekigawa³, ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ³Internal Medicine 2, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, ⁴Juntendo University Urayasu Hospital, Tokyo, Japan, ⁵Nihon Nosan Corporation, Nihon Nosan Corporation, Kanagawa, Japan, ⁶Internal Medicine and Rheumatology,, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Our previous study demonstrated changes in the profiles of serum protein biomarkers in infliximab-treated rheumatoid arthritis (RA) patients using a novel approach to proteomic…
Abstract Number: 333 • 2012 ACR/ARHP Annual Meeting
Pressure and Blood Flow Measurements in Efferent Lymphatics As Biomarkers of Arthritic Flare
Echoe M. Bouta¹, Ronald Wood², Christopher T. Ritchlin³, Lianping Xing⁴ and Edward M. Schwarz⁵, ¹University of Rochester, Rochester, NY, ²Department of Urology, University of Rochester School of Medicine and Dentistry, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁵Center for Musculoskeletal Research, University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease with episodic flares in affected joints. These flares are associated with decreased lymphatic drainage. In TNF-Tg mice,…
Abstract Number: 334 • 2012 ACR/ARHP Annual Meeting
Selective iNOS Inhibition Increases the Lymphatic Pulse and Drainage From Arthritic Joints in TNF-Tg Mice
Yawen Ju¹, Ronald Wood², Lianping Xing³, Christopher T. Ritchlin⁴ and Edward M. Schwarz⁵, ¹University of Rochester Medical Center, Rochester, NY, ²Department of Urology, University of Rochester Medical Center, Rochester, NY, ³Pathology & Lab Medicine, University of Rochester Medical Center, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Sufficient lymphatic drainage, which is partially controlled by an intrinsic lymphatic pulse, is an important mechanism to limit joint inflammation and destruction from arthritis.…
Abstract Number: 335 • 2012 ACR/ARHP Annual Meeting
Treatment with Bgp-15, a Novel Insulin Sensitizer Attenuates Collagen-Induced Arthritis in DBA/1 Mice
Peter Mandl¹, Silvia Hayer², Stephan Blüml³, Victoria Saferding¹, Despoina Sykoutri¹, Kurt Redlich² and Josef S. Smolen⁴, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: BGP-15, a small synthetic hydroxylamine derivative is a member of a new class of insulin-sensitizing medications also known as chaperone-inducers. Beside its beneficial effects…
Abstract Number: 336 • 2012 ACR/ARHP Annual Meeting
Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody^®For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile
Maarten Van Roy¹, Hans Ulrichts², Stefaan Rossenu², Sandy Jacobs², Sofie Poelmans³, Gert Verheyden², Michel Vierboom⁴, Bert 't Hart⁴, Judith Baumeister¹ and Josefin-Beate Holz⁵, ¹Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ²Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ³Pharmacology, Ablynx NV, Gent, Belgium, ⁴Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ⁵Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor IL-6R. IL-6 plays an important role in the…
Abstract Number: 337 • 2012 ACR/ARHP Annual Meeting
In Vivo Quantification of Joint Inflammation in a Murine Arthritis Model by Anato-Molecular Imaging
Smriti K. Raychaudhuri¹, Anupam Mitra¹, Kuang Gong², Jian Zhou², Jinyi Qi², Siba P. Raychaudhuri¹ and Abhijit J. Chaudhari³, ¹Rheumatology, UC Davis School of Medicine/VA Sacramento Medical Center, Mather, CA, ²Biomedical Engineering, University of California, Davis, Davis, CA, ³Radiology, UC Davis School of Medicine, Sacramento, CA
Background/Purpose: Positron Emission Tomography (PET) using the radiotracer 18F-fluorodeoxyglucose (FDG) with X-ray Computed Tomography (CT) has the ability of producing an in vivo, three-dimensional quantitative…
Abstract Number: 338 • 2012 ACR/ARHP Annual Meeting
The Potent Phosphoinositide-3-Kinase-(δ,γ) Inhibitor IPI-145 Is Active in Preclinical Models of Arthritis and Well Tolerated in Healthy Adult Subjects
James R. Porter¹, Janid Ali², Jonathan P. DiNitto², Joi Dunbar², Kerrie Faia², Jennifer Hoyt², Brianne Leary², Alice R. Lim², Christian Martin², Charlotte McKee², Patrick O'Hearn², Melissa Pink², Jennifer Proctor², John Soglia², Bonnie Tillotson², Kerry White², David G. Winkler² and Vito J. Palombella², ¹Product Development, Infinity Pharmaceuticals, Inc., Cambridge, MA, ²Infinity Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Phosphoinositide-3-kinases (PI3K) play pivotal roles in cell signaling and regulate a variety of cellular functions. PI3K-δ and PI3K-γ isoforms are necessary for adaptive and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].